Bayer said 2018 was another year of robust growth for its pharmaceuticals division in the Asia-Pacific region.
The company said the region’s sales grew 7.3 percent in 2017 to over 5.2 billion euros, with many of the region’s markets delivering strong growth rates in 2018 including Australia (7 percent), South Korea (7 percent), Taiwan (9 percent), China (16 percent), the Philippines (20 percent) and Indonesia (22 percent).
This marked the eighth consecutive year of growth for Bayer Pharmaceuticals’ sales in the Asia/Pacific since 2011. The region contributed more than 30 percent to the division’s global sales and continued to be the fastest growing reporting region for Bayer’s Pharmaceutical business.
“Our strong performance year after year speaks to the strong demand for our innovative medicines as they deliver significant benefits to patients battling serious diseases such as cardiovascular diseases, cancer, and eye diseases related to aging and diabetes. We will continue to bring new and better treatments to patients in the region and build more collaboration with external partners here,” said Bayer Pharmaceuticals Division Asia/Pacific senior vice president and head of commercial operations Claus Zieler.
In 2018, Bayer’s key products such as oral anticoagulant medicine, eye medicine and oral cancer treatment continued to be well received by doctors and patients in Asia/Pacific.
By the end of 2018, nearly 48 million packs of oral anticoagulant medicine have been delivered to patients in Asia/Pacific for blood clot prevention and treatment in several indications across the venous and arterial thromboembolic space and about 3.5 million doses of eye medicine have been administered to patients in Asia/Pacific for treatment of several retinal disorders including wet age-related macular degeneration and diabetic macular edema since launch.